Parker Geoffrey M. 4
4 · Allogene Therapeutics, Inc. · Filed Oct 23, 2025
Insider Transaction Report
Form 4
Parker Geoffrey M.
CHIEF FINANCIAL OFFICER
Transactions
- Sale
Common Stock
2025-10-21$1.26/sh−36,744$46,169→ 1,276,796 total
Footnotes (2)
- [F1]Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F2]Pursuant to an employee stock purchase program, includes 6,000 shares of the Issuer's common stock acquired by the reporting person on March 14, 2025 and 6,000 shares of the Issuer's common stock acquired by the reporting person on September 15,2025.